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OBJECTIVES We sought to determine the incidence, clinical features, and risk factors for retroperitoneal
hematoma (RPH) after percutaneous coronary intervention (PCI).
BACKGROUND Little is known about the clinical features, outcomes, and determinants of this serious
complication in the contemporary era of PCI.
METHODS A retrospective analysis yielded 26 cases of RPH out of 3,508 consecutive patients undergoing
PCI between January 2000 and January 2004. Cases were compared with a randomly selected
sample of 50 control subjects without RPH.
RESULTS The incidence of RPH was 0.74%. Features of RPH included abdominal pain (42%), groin
pain (46%), back pain (23%), diaphoresis (58%), bradycardia (31%), and hypotension (92%).
The mean systolic blood pressure nadir was 75 mm Hg. The hematocrit dropped by 11.5 
5.1 points from baseline in RPH patients, as compared with 2.3  3.3 points in controls
(p  0.0001). The mean hospital stay was longer in RPH patients (2.9  3.8 days vs. 1.7 
1.5 days, p 0.06). The following variables were found to be independent predictors of RPH:
female gender (odds ratio [OR] 5.4, p  0.005), low body surface area (BSA 1.73 m2; OR
7.1, p  0.008), and higher femoral artery puncture (OR 5.3, p  0.013). There was no
association between RPH and arterial sheath size, use of glycoprotein IIb/IIIa inhibitors, or
deployment of a vascular closure device.
CONCLUSIONS Female gender, low BSA, and higher femoral artery puncture are significant risk factors for
RPH. Awareness of the determinants and clinical features of RPH may aid in prevention,
early recognition, and prompt treatment. (J Am Coll Cardiol 2005;45:363–8) © 2005 by
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.10.042the American College of Cardiology Foundation
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hechnical advances in percutaneous coronary intervention
PCI) have led to an overall improvement in short- and
ong-term outcomes. However, iatrogenic complications
uch as bleeding may still occur. Recent randomized studies
ndicate that vascular access site injury resulting in major
leeding remains a significant complication, with an inci-
ence of 1% to 2% (1,2), although in unselected patients,
he rate is considerably higher (3,4).
Retroperitoneal hematoma (RPH) is one of the most
erious complications after PCI. Unlike other bleeding sites,
he retroperitoneum can harbor a large volume of blood
ith few external manifestations until hypovolemia occurs,
eading to delayed recognition, added morbidity, and a
otentially fatal result. Although bleeding as a complication
f PCI has been examined previously (4–8), there are few
tudies on RPH after PCI (9,10). These small studies report
ata from the late 1980s and early 1990s from a predomi-
From the Division of Cardiovascular Medicine, Stanford University Medical
enter, Stanford, California. Dr. Farouque was supported by a Neil Hamilton Fairley
ellowship of the National Health and Medical Research Council of Australia.R
Manuscript received June 14, 2004; revised manuscript received October 14, 2004,
ccepted October 18, 2004.antly surgical perspective (9,10). Hence, the relevance of
hese studies to the current era remains uncertain. We
herefore sought to analyze the occurrence and clinical and
rocedural determinants of RPH in a contemporary sample
f patients from a single center using a case-control study
esign.
ETHODS
tudy population. A retrospective analysis of the PCI
atabase at Stanford University Medical Center between
anuary 2000 and January 2004 was undertaken. Over a
our-year interval, 3,508 PCIs were performed. The
atabase was reviewed to identify definite cases of RPH
ssociated with femoral approach PCI (n  26). Twenty-
ve patients had computed tomographic scan documen-
ation, and one patient had autopsy confirmation of
PH. To determine predictive factors of RPH, a case-
ontrol study was performed. Fifty control subjects were
andomly selected from the overall group of patients who
ad PCI via the femoral approach uncomplicated by
PH. Matching of subjects was not performed so as not
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ariables on the outcome.
rocedure. Procedural antithrombotic therapy consisted of
spirin and unfractionated heparin. Glycoprotein (GP)
Ib/IIIa receptor antagonists and coronary stents were used
t the discretion of the operator. A thienopyridine was
dministered to patients receiving a stent. Femoral artery
ngiograms were obtained by hand injection of radiographic
ontrast through the side arm of the femoral sheath in a
hallow (20°) right or left anterior oblique projection
ithout cranial or caudal angulation. A collagen (Angio
eal; St. Jude Medical, St. Paul, Minnesota) or suture-
ediated (Perclose; Abbott Vascular, Redwood Shores,
alifornia) vascular closure device was used to close the
emoral artery puncture based on operator preference.
heaths left in situ after the procedure were removed when
he activated clotting time was 180 s, and compression
as applied to achieve hemostasis.
ata collection. Detailed clinical and procedural data were
btained for all patients by reviewing database records,
harts, and catheterization laboratory logs. Hypotension was
efined as systolic blood pressure 90 mm Hg. Blood
ressure was deemed to fluctuate if the observed hemody-
amic response during the bleeding event cycled between
ypotensive and normotensive values (systolic blood pres-
ure 100 mm Hg) on at least two occasions.
An individual blinded to outcomes analyzed the femoral
rtery angiograms to determine the position of arterial
uncture. Puncture site position was arbitrarily divided into
wo categories using the femoral head as a landmark: the
roximal third of the femoral head or above (high) and the
iddle third of the femoral head or below (low). Digital
uantitative angiography of the common femoral artery was
erformed with an automated edge-detection program
GE QCA version 3.1; GE Medical Systems, Milwaukee,
isconsin), using the contrast-filled femoral sheath for
alibration. Study approval was obtained from the Institu-
ional Review Board at Stanford University Medical Center.
tatistical analysis. Data are expressed as the mean value 
D, unless otherwise indicated. For categorical variables, in-
ergroups comparisons were performed using the chi-square
est. The Fisher exact test was used if the expected cell count
or a 2  2 table was 5. The two-tailed unpaired Student t
est was used to analyze continuous variables, and the Mann-
hitney U test was used if the assumption of normality was
ot met. A p value 0.05 was considered statistically signifi-
ant. Univariate predictors with p  0.05 were entered into a
Abbreviations and Acronyms
BSA  body surface area
GP  glycoprotein
OR  odds ratio
PCI  percutaneous coronary intervention
RPH  retroperitoneal hematomaogistic regression model to determine independent factors
pssociated with the development of RPH. The odds ratio (OR)
nd 95% confidence interval were calculated. Statistical analy-
es were performed using SPSS version 11.0 software package
SPSS Inc., Chicago, Illinois).
ESULTS
aseline characteristics of the study sample are indicated in
able 1. Retroperitoneal hematoma occurred in 26 (0.74%)
f 3,508 consecutive patients undergoing PCI.
linical features and in-hospital outcome. Clinical man-
festations and the time course of RPH are indicated in
able 2 and Figure 1. Anemia was a universal feature, with
mean fall in hematocrit of 11.5 5.1 points from baseline
n RPH patients, as compared with 2.3  3.3 points in
ontrol subjects (p 0.0001). Blood transfusions were given
able 1. Baseline Characteristics
Characteristic Patients Controls
ge (yrs) 66  13 67  12
umber of risk factors per patient* 1.4  0.9 1.6  0.9
umber of preprocedural antithrombotic drugs† 1.7  1.0 1.6  0.9
ndication for PCI
Stable angina 62% 44%
Acute coronary syndrome 31% 38%
ST-segment elevation MI 8% 18%
umber of diseased coronary vessels‡ 1.9  0.9 2.2  0.9
oronary stent implantation§ 89% 93%
otational atherectomy 8% 4%
ultivessel PCI 35% 32%
eripheral vascular disease 12% 6%
Refers to the combination of hypertension, diabetes mellitus, and hyperlipidemia.
Includes the combination of aspirin, thienopyridine, heparin, glycoprotein IIb/IIIa
nhibitor, and warfarin. ‡Diameter stenosis 50% by visual assessment. §Percentage
f intervened vessels that were stented. These variables were analyzed using the
isher exact test. All other categorical variables were analyzed using the chi-square
est. There were no significant differences between the groups in the listed charac-
eristics. Data are presented as the mean value  SD or percentage.
MI  myocardial infarction; PCI  percutaneous coronary intervention.
able 2. Clinical Features of Retroperitoneal Hematoma (n  26)
Clinical Features Cases
ymptoms
Lower abdominal pain 11 (42%)
Groin pain 12 (46%)
Back pain 6 (23%)
Diaphoresis 15 (58%)
hysical signs
Abdominal tenderness 18 (69%)
External groin hematoma 8 (31%)
Bradycardia 8 (31%)
Hypotension 24 (92%)
Systolic BP nadir (mm Hg) 75.3  15.5
Diastolic BP nadir (mm Hg) 37.2  10.4
Fluctuating BP response* 11 (42%)
lood loss anemia 26 (100%)
aseline hematocrit (%) 37.8  3.4
owest hematocrit (%) 26.4  4.6
ime to first clinical feature (min)† 157.6  162.9
Percentage given as a proportion of hypotensive patients. †Time from procedure end
ntil occurrence of first clinical feature. Data are presented as the number (%) of
atients. Continuous variables are presented as the mean value  SD.
BP  blood pressure.
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February 1, 2005:363–8 Risk Factors for Retroperitoneal Hematoma After PCIo 92% of RPH patients to correct the anemia (mean 2.7 
.3 U [range 1 to 18 U]). Three patients (12%) required
ascular surgical intervention due to persistent hypotension.
wo of these patients had punctures in the distal external
liac artery, and one patient had an anterior wall common
emoral artery puncture that was inadequately sealed by a
uture-mediated closure device despite the appearance of
xternal hemostasis. These patients had successful vascular
epair and recovered uneventfully. One patient (4%) with
PH died from complications of retroperitoneal blood loss.
ll RPH episodes were ipsilateral to the femoral artery
uncture, as determined by a computed tomographic scan.
he duration of hospital stay after PCI was longer in RPH
atients than in controls (2.9  3.8 days vs. 1.7  1.5 days,
 0.06). There was one death (2%) in the control group
ue to an arrhythmic complication of acute myocardial
nfarction.
redictors of RPH. Univariate and multivariate predictors
f RPH are shown in Tables 3 and 4. Patients receiving a
igher weight-adjusted heparin dose and those with smaller
aliber femoral arteries were more likely to develop RPH, but
hese associations were of borderline statistical significance
Table 3). The use of a GP IIb/IIIa inhibitor or vascular
losure device was not predictive of RPH. Three dichotomous
ariables were identified as independent predictors of RPH
Table 4). These factors included female gender (OR 5.4),
SA1.73 m2 (OR 7.1), and a higher femoral artery puncture
ite (OR 5.3). The relationship between BSA and femoral
igure 1. Interval from procedure conclusion to onset of the first clinical
anifestation of retoperitoneal hematoma (RPH).
Table 3. Comparison of Morphometric, Labor
Variable Patients
Body mass index (kg/m2) 26.8 
Body surface area (m2)* 1.7 
Baseline hematocrit (%) 38.2 
Baseline platelet count (103/l) 230 
Baseline INR 1.1 
Creatinine clearance (ml/min)‡ 56 
Total heparin dose (U) 7,153 
Heparin dose (U/kg) 107 
Procedure duration (min) 85.3 
Femoral artery diameter (mm) 6.3 
*Body surface area was calculated using the Mosteller form
clearance as a measure of renal function was calculated using the Co
 SD.rtery size was studied using simple linear regression, and this
howed a modest correlation between the two variables (r 
.40, p  0.002) (Fig. 2).
ISCUSSION
o our knowledge, this study is the first to examine
haracteristics and predictors of RPH occurring after PCI in
he current era. Our findings indicate that RPH is an
ncommon albeit potentially serious complication of PCI.
oreover, female gender remains an independent predictor
f the occurrence of RPH, in addition to other patient- and
rocedure-related factors.
ncidence. The reported incidence of RPH after cardiac
atheterization varies. Sreeram et al. (10) documented an
ncidence of 0.15% in patients undergoing diagnostic and
nterventional cardiac catheterization between 1990 and
991. However, this figure is likely to be an underestimate,
s RPH cases were selected based on referral for vascular
urgical intervention. Others have reported an RPH inci-
ence of 0.5% after PCI during a similar era (5). In one of
he larger series, Kent et al. (9) observed RPH in 0.47% of
ll patients undergoing cardiac catheterization between
988 and 1993. In the subgroup that had PCI, the incidence
f RPH was 1% and was more frequent in patients receiving
rst-generation coronary stents than in those who had
alloon angioplasty alone (3% vs. 0.8%). Our findings are
onsistent with a subset analysis of the Do Tirofiban And
eoPro Give Similar Efficacy Outcomes Trial (TARGET),
n which RPH was seen in 0.7% of patients (7). The
ariation in frequency of RPH after PCI between these
tudies may reflect differences in periprocedural antithrom-
otic regimens and evolution of vascular access site man-
gement over the last two decades.
linical features. The early diagnosis of RPH is elusive
ue to its concealed nature. Typically, the diagnosis is made
nly after significant blood loss has occurred, as in our study.
symptomatic RPH was rare, with 96% of cases having at
east one symptom. However, some symptoms of RPH in
he setting of PCI are nonspecific, such as back or groin
iscomfort. Back pain is often regarded as a common feature
f RPH, but in this series, it was an infrequent symptom. In
, and Procedural Variables
26) Controls (n  50) p Value
28.7  5.6 0.20
2.0  0.2 0.0001†
37.8  3.4 0.75
226  57 0.81
1.1  0.3 0.71
62  21 0.24
1 7,271  2,314 0.85
89  31 0.06†
80.2  30.7 0.56
7.0  1.5 0.07
Calculated using the Mann Whitney U test. ‡Creatinineatory
(n 
6.4
0.2
4.8
48
0.1
24
2,78
46
38.4
1.3
ula. †
ckroft-Gault formula. Data are presented as the mean value
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Risk Factors for Retroperitoneal Hematoma After PCI February 1, 2005:363–8ontrast, lower abdominal pain and diaphoresis were more
ommonly observed. These are unexpected occurrences after
ncomplicated PCI and should lead the physician to con-
ider concealed bleeding as a potential cause.
The vast majority of RPH patients had evidence of
ypovolemic shock, with pronounced hypotension. In con-
rast, previous studies of RPH in both the non-PCI and
CI settings suggest a lower frequency of hypotension
ccurring in 43% to 64% (10,11). A frequent observation in
ur study among hypotensive patients was a fluctuating
lood pressure related to the balance between the rate of
ngoing bleeding and intravenous fluid resuscitation. More-
ver, several patients exhibited clinically significant brady-
ardia in association with hypotension. The low cardiac
utput and impaired coronary flow that may result from
hese hemodynamic perturbations can lead to myocardial
schemia and expose the patient to the potential risk of stent
hrombosis. Global hypoperfusion may result in deleterious
ffects in patients with preexisting disease in other arterial
eds (4).
Lower abdominal tenderness ipsilateral to the puncture
ite was another common finding and underscores the
able 4. Predictors of Retroperitoneal Hematoma Formation Aft
Variable Patients Controls
ender (female) 73% 26%
SA (1.73 m2)† 46% 13%
ypertension 65% 74%
iabetes mellitus 23% 24%
onemergent PCI 62% 44%
revious femoral artery puncture 50% 62%
igh femoral puncture 55% 16%
rterial sheath size (7-F) 50% 35%
enous sheath insertion 27% 29%
eparin (85 U/kg) 58% 41%
lycoprotein IIb/IIIa use 69% 61%
ascular closure device 85% 72%
The p values for univariate analyses were calculated using the chi-square test. †Body s
ith the combined upper three quartiles (1.73–2.44 m2).
BSA  body surface area; CI  confidence interval; OR  odds ratio; PCI  pi
igure 2. Simple linear regression plot demonstrating the relationship
etween body surface area and femoral artery diameter.mportance of a careful physical examination of the abdo-
en in evaluating suspected cases of RPH. Previous studies
ave documented clinical evidence of femoral neuropathy in
3% to 54% of RPH patients, caused by compression of the
emoral nerve, which was treated with surgery in some cases
9–11). However, overt manifestations of femoral neurop-
thy were absent in our study. This discrepancy may be due
o differences in the size and location of the hematoma in
elation to the femoral nerve or variability in reporting
ubtle lower limb neurologic changes. It is instructive to
xamine the timing of the initial manifestation of RPH in
elation to PCI. Almost 75% of cases presented within the
rst 3 h after conclusion of the procedure, with a rapid
ecline in frequency after this time period, suggesting that
ncreased vigilance during the first few postprocedural hours
ay be important.
It has been suggested that some cases of RPH after
ardiac catheterization may be unrelated to femoral artery
uncture and are more likely due to altered hemostasis.
sing computed tomographic imaging, Quint et al. (12)
ound that 25% of retroperitoneal bleeds were remote from
he site of femoral artery puncture, with the majority of
hese being on the contralateral side to the puncture site.
owever, we found that all instances of RPH were ipsilat-
ral to the femoral puncture site and contiguous with the
resumed site of vessel puncture in the inguinal region. Our
bservations imply that femoral artery puncture was an
ntegral element to the formation of RPH in all cases.
utcomes. The most serious complication secondary to
CI-related RPH is death. In our study the mortality rate as
consequence of RPH was 4%, which is in accordance with
revious reports (9,10). A frequent requirement was the
ransfusion of blood to correct anemia. Although it is
egarded as a safe and often life-saving therapy, blood
ransfusion is not without risks. Moreover, a recent study of
0,974 patients indicated that major bleeding and blood
ransfusion after PCI were both independent predictors of
rcutaneous Coronary Intervention
Univariate Analysis Multivariate Analysis
R (95% CI) p Value* OR (95% CI) p Value
(2.65–22.73) 0.0001 5.44 (1.66–17.90) 0.005
(1.85–18.55) 0.002 7.05 (1.65–30.02) 0.008
(0.24–1.85) 0.43 — —
(0.31–2.91) 0.92 — —
(0.67–5.08) 0.34 — —
(0.24–1.60) 0.31 — —
(1.82–21.74) 0.004 5.26 (1.41–19.61) 0.013
(0.72–4.96) 0.20 — —
(0.32–2.67) 0.88 — —
(0.74–5.26) 0.17 — —
(0.52–3.92) 0.49 — —
(0.62–7.33) 0.23 — —
area was divided into quartiles, and the lowest quartile (1.36–1.73 m2) was compared
neous coronary intervention.er Pe
O
7.75
5.86
0.66
0.95
1.84
0.61
6.33
1.88
0.92
1.97
1.43
2.13
urfacen-hospital and one-year mortality (4). Another contributor
t
i
d
f
T
s
i
t
R
e
a
o
1
a
P
i
a
f
s
o
t
w
n
fi
e
p
b
s
e
a
w
c
f
a
c
a
t
p
r
b
a
T
p
b
T
f
a
a
a
A
t
t
i
a
i
b
t
fl
R
a
s
c
i
w
p
(
t
t
c
t
c
a
t
t
b
c
i
h
n
i
t
E
i
a
t
w
s
c
e
e
t
e
R
r
b
a
w
b
i
(
p
l
o
i
i
a
367JACC Vol. 45, No. 3, 2005 Farouque et al.
February 1, 2005:363–8 Risk Factors for Retroperitoneal Hematoma After PCIo morbidity in our study was the need for vascular surgical
ntervention, which was required in 12% of RPH cases. Our
ata are consistent with the findings of Kent et al. (9), who
ound that 16% of cases in their series required an operation.
hese observations indicate that the majority of patients can
till be managed conservatively without resorting to surgical
ntervention. Due to these factors, there was a strong trend
oward increased length of hospital stay in patients with
PH. In addition, the occurrence of RPH has significant
conomic implications. Bleeding after PCI is known to be
n important contributor to hospital costs. A recent analysis
f a large U.S. hospital claims database between 1995 and
997 indicated that bleeding complications resulted in the
ddition of over $10,000 to the baseline cost of PCI (3).
redictors. The findings of this study underscore the
mportance of female gender, even after correction for BSA,
s an independent predisposing factor for the occurrence of
emoral vascular access site complications (8,13). Only one
tudy has previously addressed risk factors for the occurrence
f RPH. Kent et al. (9) found that women were more likely
o have RPH after coronary stenting, but only 13 RPH cases
ere analyzed, and details of the multivariate analysis were
ot reported. Our results corroborate and extend this
nding to the current era, in addition to providing an
stimate of risk. The reason for the intriguing female
redisposition to RPH after PCI is unclear. Several possi-
ilities exist, including gender-related differences in arterial
tructure and function related to the vascular effects of
strogen (14,15). Although menopausal status was not
scertained in this study, it is likely that the majority of
omen were postmenopausal given their age range. It is
onceivable that such alterations may predispose to arterial
ragility and vascular complications such as RPH. Women
re also known to have smaller diameter and shorter length
ommon femoral arteries than men (16), which may make
ccess more challenging. This anatomic difference may lead
o a greater likelihood of multiple arterial and posterior wall
unctures. Gender-specific differences and menopause-
elated changes in coagulation and fibrinolysis have also
een documented (17), but these alterations are complex
nd may not predispose to an increase in bleeding risk.
here are also gender differences in arterial mechanical
roperties, such as increased pulsatility, possibly related to
ody size (18), which could increase bleeding risk.
A low BSA was another independent predictor of RPH.
his may be partly due to its association with a smaller
emoral artery diameter, resulting in arterial access issues, as
lluded to earlier. The use of a micropuncture technique to
ccess the femoral artery may reduce the impact of multiple
rterial punctures, although this hypothesis is untested.
ccess via the radial artery could also be considered in order
o minimize access site bleeding.
A higher femoral arterial puncture site, defined as above
he middle third of the femoral head on fluoroscopy, was an
mportant procedure-related risk factor for RPH. Puncture
nd sheath insertion above the inguinal ligament, and hence ento the external iliac artery, may predispose to uncontrolled
leeding due to the difficulty in achieving compression of
his vessel. Meticulous attention to puncture technique with
uoroscopic guidance may minimize the occurrence of
PH. However, it is important to realize that a lower
rterial puncture does not eliminate the risk of RPH. In our
tudy, 45% of patients with RPH had sheath insertion in the
ommon femoral artery well below the presumed site of the
nguinal ligament. The occurrence of RPH in these cases
as most likely related to the spread of bleeding from the
uncture site along well-defined anatomic fascial planes
19). Specifically, bleeding from the femoral vascular struc-
ures contained within the femoral sheath can extend into
he retroperitoneum by virtue of its superiorly directed
ommunication with this space. Because the vascular struc-
ures at this location are accessible to effective manual
ompression, we advocate applying this simple measure at
n early stage to all cases of presumed RPH until stabiliza-
ion of the patient is achieved and the diagnosis confirmed.
Glycoprotein IIb/IIIa inhibitors are potent blockers of
he final common pathway of platelet aggregation and have
een shown to increase the risk of vascular access site
omplications (6,8). Our findings indicate that GP IIb/IIIa
nhibitor use did not predispose to the occurrence of RPH;
owever, this conclusion needs to be tempered by the small
umber of RPH cases. Before using these agents in any
ndividual patient, an assessment of bleeding risk in relation
o the potential benefits of therapy should be obtained.
arly studies had also suggested that higher doses of heparin
n conjunction with GP IIb/IIIa use increased vascular
ccess site bleeding (8). In the present study, there was a
rend toward an increase in RPH in patients receiving larger
eight-adjusted heparin doses. Several measures have been
uggested to minimize the risk of femoral access site
omplications when using GP IIb/IIIa inhibitors, including
arly sheath removal, avoiding the use of venous sheaths,
nsuring reduced weight-adjusted heparin dosing, and op-
imal post-PCI nursing care (6,8,20).
Alternative antithrombotic regimens should be consid-
red in patients deemed to be at higher risk of RPH. In the
andomized Evaluation in PCI Linking Angiomax to
educed Clinical Events (REPLACE-2) randomized trial,
ivalirudin with provisional GP IIb/IIIa blockade was
ssociated with fewer major bleeding events, as compared
ith unfractionated heparin and planned GP IIb/IIIa
lockade in patients with low- to moderate-risk character-
stics (21). Specifically, there was a 60% reduction in RPH
p  0.06), without a significant change in ischemic end
oints. The use of preprocedural high-dose clopidogrel
oading without GP IIb/IIIa antagonists may be another
ption (2).
Vascular closure device deployment is relatively common
n the current era of PCI. Potential advantages include
mproved patient comfort by avoiding manual compression
nd reduced time to ambulation. However, there is some
vidence to suggest that vascular closure device use may be
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Risk Factors for Retroperitoneal Hematoma After PCI February 1, 2005:363–8ssociated with an increased risk of access site bleeding (22).
n contrast, our findings and those of others suggest that
leeding may not be increased in patients receiving closure
evices (7). The discrepant findings between these nonran-
omized studies of vascular closure device use could be
ttributed to differences in the characteristics of the respec-
ive study populations and their predisposition to the
evelopment of vascular complications. To adequately assess
he impact of closure devices on vascular complications, a
andomized trial assessing outcomes would be required.
evertheless, in the PCI setting, these devices are typically
eployed in highly anticoagulated patients, and their use
ay engender a perception of lower bleeding risk among
taff involved in early post-PCI management. Patients
eceiving closure devices should therefore be closely ob-
erved to ensure early detection of bleeding complications
uch as RPH.
tudy limitations. This study is a retrospective case-
ontrol review, and although it represents the largest pub-
ished series to date reporting the manifestations and risk
actors of PCI-related RPH, the number of cases (n  26)
imits the analysis. The case-control design is well suited to
tudying an uncommon outcome such as RPH. A random
ample of 50 patients from the overall group of 3,482
atients who did not have RPH was selected as the control
roup for the case-control analysis. This method permits an
nbiased estimation of parameters and, for practical consid-
rations, enabled a complete and detailed examination of
linical, procedural, and outcome variables.
onclusions. Retroperitoneal hematoma is a serious vas-
ular access site complication of PCI. Several factors may
redispose to RPH in the current era of PCI, including
emale gender, low BSA, and higher femoral artery punc-
ure. Awareness of the clinical features and determinants of
PH may aid in prevention, earlier recognition, and prompt
herapy of this complication.
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